BACKGROUND: Neoadjuvant radiation therapy (RT) has several theoretical benefits in the treatment of retroperitoneal sarcoma (RPS), but concerns remain about treatment toxicity and perioperative morbidity. There are limited data regarding its effect on perioperative outcomes, most of which come from small, single-institution series. The purpose of this study was to evaluate the short-term (30-day) postoperative morbidity and mortality associated with neoadjuvant RT following resection of RPS. METHODS: The 2005-2011 National Surgical Quality Improvement Program Participant User File was queried for patients undergoing RPS resection. Subjects were stratified by use of neoadjuvant RT. Perioperative variables and short-term 30-day outcomes were compared. Groups were then propensity matched using a 2:1 nearest-neighbor algorithm and multivariable logistic regression was performed to assess neoadjuvant RT as a predictor of short-term 30-day outcomes. RESULTS: A total of 785 patients were identified. Neoadjuvant RT was administered to 71 (9.0%). Patients who received neoadjuvant RT were slightly younger (56 vs. 62 years, p < 0.001), but otherwise the groups were similar. After propensity matching, all baseline characteristics were highly similar. Median operative time was longer in the neoadjuvant RT group (279 vs. 219 min, p < 0.01), but there were no differences in mortality (1.4 vs. 2.1%, p = 0.71), major complications (28.2 vs. 25.2%, p = 0.69), overall complications (35.2 vs.33.2%, p = 0.83), early reoperation (5.6 vs. 7.4%, p = 0.81), or length of stay (7 vs. 7 days, p = 0.56). Following further adjustment with logistic regression, we confirmed that there were no differences in 30-day mortality or morbidity between patients who did and did not receive neoadjuvant RT. CONCLUSIONS: Neoadjuvant RT does not appear to increase short-term (30-day) morbidity or mortality following resection of RPS. Continued investigation is needed to better define the role for radiation therapy among patients with this disease.
BACKGROUND: Neoadjuvant radiation therapy (RT) has several theoretical benefits in the treatment of retroperitoneal sarcoma (RPS), but concerns remain about treatment toxicity and perioperative morbidity. There are limited data regarding its effect on perioperative outcomes, most of which come from small, single-institution series. The purpose of this study was to evaluate the short-term (30-day) postoperative morbidity and mortality associated with neoadjuvant RT following resection of RPS. METHODS: The 2005-2011 National Surgical Quality Improvement Program Participant User File was queried for patients undergoing RPS resection. Subjects were stratified by use of neoadjuvant RT. Perioperative variables and short-term 30-day outcomes were compared. Groups were then propensity matched using a 2:1 nearest-neighbor algorithm and multivariable logistic regression was performed to assess neoadjuvant RT as a predictor of short-term 30-day outcomes. RESULTS: A total of 785 patients were identified. Neoadjuvant RT was administered to 71 (9.0%). Patients who received neoadjuvant RT were slightly younger (56 vs. 62 years, p < 0.001), but otherwise the groups were similar. After propensity matching, all baseline characteristics were highly similar. Median operative time was longer in the neoadjuvant RT group (279 vs. 219 min, p < 0.01), but there were no differences in mortality (1.4 vs. 2.1%, p = 0.71), major complications (28.2 vs. 25.2%, p = 0.69), overall complications (35.2 vs.33.2%, p = 0.83), early reoperation (5.6 vs. 7.4%, p = 0.81), or length of stay (7 vs. 7 days, p = 0.56). Following further adjustment with logistic regression, we confirmed that there were no differences in 30-day mortality or morbidity between patients who did and did not receive neoadjuvant RT. CONCLUSIONS: Neoadjuvant RT does not appear to increase short-term (30-day) morbidity or mortality following resection of RPS. Continued investigation is needed to better define the role for radiation therapy among patients with this disease.
Authors: Bruce L Hall; Barton H Hamilton; Karen Richards; Karl Y Bilimoria; Mark E Cohen; Clifford Y Ko Journal: Ann Surg Date: 2009-09 Impact factor: 12.969
Authors: Sean M McBride; Chandrajit P Raut; Michelle Lapidus; Phillip M Devlin; Karen J Marcus; Monica Bertagnolli; Suzanne George; Elizabeth H Baldini Journal: Ann Surg Oncol Date: 2013-02-08 Impact factor: 5.344
Authors: Myles J F Smith; Paul F Ridgway; Charles N Catton; Amanda J Cannell; Brian O'Sullivan; Lynn A Mikula; Julia J Jones; Carol J Swallow Journal: Radiother Oncol Date: 2014-01-07 Impact factor: 6.280
Authors: Elizabeth H Baldini; Michelle R Lapidus; Qian Wang; Judith Manola; Dennis P Orgill; Bohdan Pomahac; Karen J Marcus; Monica M Bertagnolli; Phillip M Devlin; Suzanne George; John Abraham; Marco L Ferrone; John E Ready; Chandrajit P Raut Journal: Ann Surg Oncol Date: 2012-12-15 Impact factor: 5.344
Authors: Timothy M Pawlik; Peter W T Pisters; Lynn Mikula; Barry W Feig; Kelly K Hunt; Janice N Cormier; Matthew T Ballo; Charles N Catton; Julia J Jones; Brian O'Sullivan; Raphael E Pollock; Carol J Swallow Journal: Ann Surg Oncol Date: 2006-02-24 Impact factor: 5.344
Authors: Edmund K Bartlett; Robert E Roses; Chelsey Meise; Douglas L Fraker; Rachel R Kelz; Giorgos C Karakousis Journal: J Surg Oncol Date: 2013-12-30 Impact factor: 3.454
Authors: Daniel P Nussbaum; Paul J Speicher; Brian C Gulack; Asvin M Ganapathi; Brian R Englum; David G Kirsch; Douglas S Tyler; Dan G Blazer Journal: Ann Surg Date: 2015-07 Impact factor: 12.969
Authors: Andrew J Bishop; Gunar K Zagars; Keila E Torres; Kelly K Hunt; Janice N Cormier; Barry W Feig; B Ashleigh Guadagnolo Journal: Int J Radiat Oncol Biol Phys Date: 2015-05-02 Impact factor: 7.038
Authors: Rebekka Götzl; Sebastian Sterzinger; Sabine Semrau; Nikolaos Vassos; Werner Hohenberger; Robert Grützmann; Abbas Agaimy; Andreas Arkudas; Raymund E Horch; Justus P Beier Journal: Health Qual Life Outcomes Date: 2019-11-08 Impact factor: 3.186
Authors: Brooke C Bredbeck; Lia D Delaney; Varun G Kathawate; Cameron A Harter; Jodi Wilkowski; Rashmi Chugh; Kyle C Cuneo; Lesly A Dossett; Michael S Sabel; Christina V Angeles Journal: J Surg Oncol Date: 2022-03-03 Impact factor: 2.885